HealthQuill Clinical trials
Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after it failed to meet its main efficacy goal.
Drugs Health Pharma

Organon halts endometriosis drug trial as it fails to meet efficacy goal

HQ Team July 2, 2025: Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after.

Read More
A majority of clinical research on adult Attention Deficit Hyperactivity Disorder (ADHD) suffers from serious methodological shortcomings, making it difficult to use the results in practice, according to researchers from the University of Copenhagen and the University of São Paulo.
Drugs Health Research

Researchers find serious flaws in clinical trials with adult ADHD patients

HQ Team July 2, 2025: A majority of clinical research on adult Attention Deficit Hyperactivity Disorder (ADHD) suffers from serious methodological shortcomings, making.

Read More
Amgen Inc.’s drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer compared to chemotherapy alone, according to a company statement.
Drugs Health Pharma

Amgen’s trial drug for gastric cancer patients helps them live longer

HQ Team June 30, 2025: Amgen Inc.’s experimental drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer.

Read More
Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants, showed patients lost about 23% of their body weight compared to a dummy group’s 2-3%.
Drugs Health Pharma

Novo Nordisk’s obesity drug CagriSema cuts weight by 23%

HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,.

Read More
Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their weight in a small study, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s amycretin drug helps obese adults lose 24% weight

HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.

Read More
The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’ living cells to China and other “hostile countries” for the fear of genetic data misuse.
Drugs Health Pharma

US to review trials to stop genetic data misuse by China, ‘hostile’ nations

HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.

Read More
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More
Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive top-line results” on the efficacy and safety of the treatment in adults, according to the company.
Drugs Health Pharma

Merck’s oral pill for bad cholesterol shows ‘positive’ data during trials

HQ Team June 10, 2025: Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive.

Read More
The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV) in infants up to one year of age for the first RSV season.
Drugs Health Pharma

Merck & Co.’s RSV injection for infants gets nod from US drug regulator

HQ Team June 10, 2025: The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV).

Read More
A third of patients with a type of blood cancer, especially those whose disease had returned or not responded to other treatments, have shown “promising” results in an early Johnson & Johnson trial.
Drugs Health Pharma

A third of blood cancer cases in J&J trials live without detectable cancer 

HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not.

Read More